Preliminary, open-label, pilot study of add-on oral Δ9-tetrahydrocannabinol in chronic post-traumatic stress disorder

Preliminary, open-label, pilot study of add-on oral Δ9-tetrahydrocannabinol in chronic post-traumatic stress disorder.

Many patients with post-traumatic stress disorder (PTSD) achieve but partial remission with current treatments. Patients with unremitted PTSD show high rates of substance abuse.

Marijuana is often used as compassion add-on therapy for treatment-resistant PTSD. This open-label study evaluates the tolerance and safety of orally absorbable Δ(9)-tetrahydrocannabinol (THC) for chronic PTSD.

Conclusion, Orally absorbable Δ(9)-THC was safe and well tolerated by patients with chronic PTSD.

PMID: 24935052 [PubMed - in process]

http://www.ncbi.nlm.nih.gov/pubmed/24935052


This Research and Resources page is sponsored by the Ohio Rights Group Education Fund.
Please support our charitable and educational work by making a generous tax deductible donation.